Drugs / CIBINETIDE
CIBINETIDE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02070783 | Feb 2012 → Feb 2013 | depressive disorder | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06626971 | Apr 2016 → May 2017 | diabetic macular edema | Belfast Health and Social Care Trust | Terminated | No outcome recorded |
| Phase 2 | NCT02039687 | Jan 2014 → Jan 2015 | sarcoid neuropathy | Araim Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01933529 | Oct 2013 → Jun 2014 | glucose intolerance, prediabetes syndrome, type 2 diabetes mellitus | Claes-Göran Östenson | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIBINETIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545305 ↗ |
| Known as | ARA 290 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02039687 ↗ |
| Known as | Cibinetida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545305 ↗ |
| Known as | Ph-bsp | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545305 ↗ |
| Action | Activate | “activates the innate repair receptor” NCT02039687 ↗ |
| Modality | Peptide | “A small peptide” NCT02039687 ↗ |
| Route | Subcutaneous | “ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.” NCT01933529 ↗ |